What the research says about ARA-290 (cibinetide)

What ARA-290 is

ARA-290, also called cibinetide, is a small peptide designed from the three-dimensional structure of erythropoietin (EPO). The insight behind it is that EPO's two main effects run through different receptors: red-cell production is driven by an EPO-receptor homodimer, while tissue protection is mediated by a separate heteromeric complex of the EPO receptor and the beta-common receptor, sometimes called the innate repair receptor (IRR) ^[9]. ARA-290 was engineered to selectively activate the tissue-protective IRR while not stimulating erythropoiesis, avoiding the rise in red-cell mass, platelet activation, and thrombosis risk that limits recombinant EPO for tissue protection ^[9].

ARA-290 is not an approved medicine; it has been an investigational compound. Material sold by research-chemical vendors is not an approved pharmaceutical product and is offered for laboratory and research use only.

What the human research has measured

The most developed human evidence is in small-fiber neuropathy complicating sarcoidosis. In an exploratory double-blind, placebo-controlled trial, 22 patients with sarcoidosis and symptoms of small-fiber neuropathy received ARA-290 or placebo over four weeks, with pain intensity and a neuropathy symptom score as endpoints ^[2]. A separate blinded, placebo-controlled trial tested daily subcutaneous ARA-290 over 28 days in sarcoidosis-associated small-nerve-fiber loss and damage ^[3]. A later phase 2b, 28-day randomized trial in 64 subjects used corneal confocal microscopy and skin nerve-fiber markers as surrogate endpoints alongside pain and functional capacity, including the six-minute walk test ^[4].

A review of two of these phase 2 trials concluded that ARA-290 treatment was consistently associated with a significant improvement of neuropathic-pain symptoms in sarcoidosis patients, seen as a decrease in pain scores ^[1]. Beyond sarcoidosis, a phase 2 study evaluated ARA-290 in type 2 diabetes with painful neuropathy ^[5], and a small phase 2 trial in diabetic macular edema enrolled nine patients over twelve weeks to measure visual and retinal outcomes ^[6].

These are small, early-phase studies, often with exploratory or surrogate endpoints, rather than large confirmatory trials. They suggest a direction of effect in specific neuropathy populations but do not establish broad efficacy.

What the preclinical work has measured

The tissue-protective mechanism has been examined in animal and cell models. In a mouse study of chemically induced colitis, both cibinetide and EPO improved the clinical course, weight gain, and survival; although this record is indexed as "human," the experiment was performed in mice ^[7]. In a laboratory study of human pancreatic islets cultured with inflammatory cytokines, cibinetide was tested for islet-protective effects relevant to transplantation, an in-vitro experiment rather than a clinical trial ^[8].

These preclinical findings are consistent with the innate-repair-receptor mechanism proposed for the peptide, but they are model systems, not clinical outcomes.

What the trials report on safety and adverse events

A central design goal of ARA-290 was to avoid the hematologic risks of EPO, and the reviews frame its selectivity for the innate repair receptor as the reason it does not raise red-cell mass ^[9]. In the phase 2 study in type 2 diabetes and painful neuropathy, in which subjects self-administered the peptide daily for 28 days and were then followed for a further month, the investigators reported that no potential safety issues were identified ^[5]. The diabetic-macular-edema trial included adverse events and antibodies to cibinetide among its assessed outcomes ^[6].

These are small, short, early-phase datasets, so the safety picture is preliminary and does not amount to a large controlled safety database. None of this is a safety guarantee or a prediction for any individual. Material sold by research-chemical vendors is not an approved product and has not passed an equivalent evaluation. This is not medical advice; consult a qualified professional and read the studies directly.

How strong is the evidence

The evidence is characterized as moderate: ARA-290 has been through several small, randomized, placebo-controlled phase 2 trials in humans, mainly for sarcoidosis-associated small-fiber neuropathy, with a consistent reported direction of benefit on pain symptoms ^[1][2][4]. What holds it back from a stronger characterization is scale and stage, the trials are small, exploratory, and often rely on surrogate endpoints, and there are no large confirmatory trials or approvals here. "Moderate" describes the design and quantity of the human trials, not a verdict that the compound works.

Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.